Kyverna Therapeutics is a pre-commercial biotechnology company with zero revenue, entirely dependent on external financing to fund its pipeline. The investment thesis hinges on the successful clinical development and potential commercialization of its therapie...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.63+7.1% vs -$0.68 | — vs — |
Q3 2026 Aug 11, 2026 | -$0.63+6.0% vs -$0.67 | — vs — |
Q2 2026 May 12, 2026 | -$0.66+12.0% vs -$0.75 | — vs — |
Q2 2026 Mar 26, 2026 | -$0.80+5.3% vs -$0.84 | — vs — |
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel's differentiated construct
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:
Benchmark KYTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Kyverna Therapeutics, Inc. (KYTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.22 | $378.15M | -1.71 | — | — | -64.67% | — | |
| $2.00 | $326.11M | -1.22 | — | — | -128.27% | — | |
| $1.78 | $473.74M | -1.65 | 646.68% | -238.62% | -178.58% | — | |
| $33.62 | $6.94B | -12.14 | — | -7585.86% | -69.59% | — | |
| $24.50 | $2.52B | -30.25 | 120.01% | -54.75% | -7.7% | — | |
| $18.57 | $3.43B | -11.61 | 64.04% | -7.21% | -8.7% | — |
Kyverna Therapeutics, Inc. (KYTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Kyverna Therapeutics, Inc. (KYTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 27, 2026·SEC
Jul 9, 2026·SEC
Get notified when KYTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kyverna Therapeutics, Inc. (KYTX) stock FAQ — growth, dividends, profitability & financials explained
Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $152.6M for fiscal year 2025.
Kyverna Therapeutics, Inc. (KYTX) has a return on equity (ROE) of -64.7%. Negative ROE indicates the company is unprofitable.
Kyverna Therapeutics, Inc. (KYTX) had negative free cash flow of $159.4M in fiscal year 2025, likely due to heavy capital investments.
